It combines in silico target identification with cancer-specific, biomarker-led validation in cancer cell lines, patient samples, translational toxicity models and in vivo studies to identify potent, safer and more selective targets early. Modality agnostic, NeoTargets advances programs in small molecules, cyclic peptides, RNAi and bifunctionals and works with partners to generate validated targets, lead compounds and partnership-ready oncology assets for the European biotech pipeline. Its platform has delivered proof of concept in AML target discovery and supports multiple collaborations with innovative drug development companies.
NeoTargets AB
NeoTargets is a Swedish oncology-focused biotech company developing de-risked cancer drug discovery programs through its proprietary oncotarget platform.
